Plain-English translation of NCT05751941 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called , which is a type of immune therapy that trains your body's immune system to fight prostate cancer cells. You'll be randomly assigned to receive this medication either while continuing to take your current hormone-blocking pills, or after stopping those pills. The goal is to understand which approach helps your immune system work better against your cancer.
Some men with advanced prostate cancer develop resistance to hormone-blocking pills, meaning their cancer starts growing again despite the treatment. This trial is exploring whether adding an immune therapy—or switching to an immune therapy alone—might help when those hormone pills stop working.
If you enroll, you'll be randomly assigned to one of two groups: one group will continue taking their hormone-blocking pills while receiving the immune therapy, and the other group will stop their hormone pills while receiving the same immune therapy. The immune therapy involves a series of infusions. Throughout the trial, you'll have regular blood tests and scans to monitor how your cancer is responding and how well the treatment is working.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States